Pulse Biosciences Reports Positive Clinical Data for Cardiac Catheter System
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 hours ago
0mins
Should l Buy PLSE?
Source: Yahoo Finance
- Impressive Clinical Results: Pulse Biosciences presented data at the Heart Rhythm 2026 meeting showing a 100% procedural success rate at 6 months (95/95) and 96% at 12 months (51/53) for its nPulse Cardiac Catheter System, indicating high efficacy and durability in treating atrial fibrillation.
- Enhanced Procedural Efficiency: The system demonstrated a left atrial dwell time of 18.6 minutes, total procedure time of 60.2 minutes, fluoroscopy time of 9.4 minutes, and an average of 12.3 applications per patient, suggesting significant improvements in procedural execution that could enhance patient treatment experiences.
- Maintained Safety Profile: Among 177 patients, only 3 (1.7%) experienced serious adverse events related to the primary safety endpoint, underscoring the safety of the technology in clinical applications and boosting confidence among physicians and patients alike.
- Multi-Center Study Validation: Conducted across 7 investigators in Europe with 177 patients, the consistency and durability of results provide a solid foundation for future clinical applications, potentially driving widespread adoption of this technology in atrial fibrillation treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PLSE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PLSE
Wall Street analysts forecast PLSE stock price to fall
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 24.250
Low
22.00
Averages
22.00
High
22.00
Current: 24.250
Low
22.00
Averages
22.00
High
22.00
About PLSE
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. It is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. It is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pulse Biosciences Reports Positive Clinical Data for Cardiac Catheter System
- Impressive Clinical Results: Pulse Biosciences presented data at the Heart Rhythm 2026 meeting showing a 100% procedural success rate at 6 months (95/95) and 96% at 12 months (51/53) for its nPulse Cardiac Catheter System, indicating high efficacy and durability in treating atrial fibrillation.
- Enhanced Procedural Efficiency: The system demonstrated a left atrial dwell time of 18.6 minutes, total procedure time of 60.2 minutes, fluoroscopy time of 9.4 minutes, and an average of 12.3 applications per patient, suggesting significant improvements in procedural execution that could enhance patient treatment experiences.
- Maintained Safety Profile: Among 177 patients, only 3 (1.7%) experienced serious adverse events related to the primary safety endpoint, underscoring the safety of the technology in clinical applications and boosting confidence among physicians and patients alike.
- Multi-Center Study Validation: Conducted across 7 investigators in Europe with 177 patients, the consistency and durability of results provide a solid foundation for future clinical applications, potentially driving widespread adoption of this technology in atrial fibrillation treatment.
See More
Pulse Biosciences Reports Positive Clinical Data for Cardiac Catheter System
- Clinical Data Highlights: Pulse Biosciences presented positive clinical data for its nPulse Cardiac Catheter System at the Heart Rhythm meeting, showing a 100% procedural success rate at 6 months among 95 patients, indicating high efficiency and durability of the technology.
- Significant Long-term Outcomes: At the 12-month follow-up, 96% of 53 patients achieved procedural success, with a 90% freedom rate from atrial fibrillation, underscoring the potential and reliability of this technology in treating atrial fibrillation.
- Enhanced Procedural Efficiency: The average procedure time was 60.2 minutes with an 18.6-minute left atrial dwell time, demonstrating consistency and efficiency across multiple investigator sites, which could redefine treatment standards for atrial fibrillation ablation.
- Good Safety Profile: Among 177 patients, only 1.7% experienced serious adverse events related to the primary safety endpoint, indicating the clinical safety of the technology and enhancing its competitive position in the market.
See More
Pulse Biosciences Showcases nPulse Technology at HRS 2026
- Clinical Trial Updates: Pulse Biosciences will present the latest clinical trial results of its nPulse™ cardiac catheter at the 2026 Heart Rhythm Society Annual Meeting, particularly focusing on one-year outcomes from a European feasibility study for atrial fibrillation, which is expected to provide significant long-term data and enhance the company's influence in the cardiac medical market.
- Live Case Transmission: The company will conduct a live case transmission during the PFA Live Case Summit, showcasing the use of nPulse™ technology in treating atrial fibrillation, emphasizing procedural workflow and real-time performance, which will further elevate market awareness and application potential of its technology.
- Multicenter Experience Sharing: At the HRS 2026, Pulse Biosciences will share multicenter experiences using compliant catheters for nanosecond pulsed field ablation to treat atrial fibrillation, which is expected to provide new insights for clinical practice and promote broader application of this technology.
- Innovative Technology Showcase: The company will showcase its innovative nanosecond pulsed field ablation technology at several events, which is anticipated to attract the attention of medical professionals and further solidify its leadership position in the field of bioelectric medicine.
See More
Pulse Biosciences to Host Analyst Event on nPulse Data
- Clinical Data Presentation: Pulse Biosciences will host an analyst event on April 25, 2026, in Chicago, where it will present late-breaking data from its European feasibility study for atrial fibrillation, which is expected to positively influence the company's future clinical development strategy.
- Technology Innovation Overview: The company's proprietary nPulse™ technology employs nanosecond pulsed field ablation (nsPFA™) energy to non-thermally clear cells while sparing adjacent non-cellular tissue, showcasing its potential applications in healthcare.
- Diverse Event Format: The analyst event will be conducted in a hybrid format, offering both in-person and online webcast options, facilitating participation from investors across different regions and enhancing interaction between the company and its investors.
- Replay Availability: Following the event, attendees can access a replay on the company's investor website under the 'Events Calendar and Presentations' section, ensuring that key information is available to those unable to attend live.
See More
Pulse Biosciences Appoints New COO
- Executive Appointment: Pulse Biosciences has appointed Liane Teplitsky as Chief Operating Officer, bringing 20 years of experience in medical technology, including her recent role as CEO of Artedrone, which is expected to enhance operational efficiency and market expansion.
- Role Expansion: David Kenigsberg's role has been expanded to full-time Chief Medical Officer, indicating the company's commitment to strengthening its medical leadership, aimed at enhancing product development and clinical strategy to support future business growth.
- Market Performance: In pre-market trading, PLSE shares were priced at $19, down 0.31%, reflecting a cautious market sentiment regarding the company's new appointments, which may impact investor confidence.
- Industry Background: Teplitsky has held senior marketing and commercial leadership roles at Abbott Laboratories and St. Jude Medical, and her extensive industry experience is expected to bring new perspectives and strategic direction to Pulse Biosciences.
See More
Pulse Biosciences Launches Atrial Fibrillation Study with First Patient Enrollment
- Trial Launch: Pulse Biosciences has enrolled the first patients in its pivotal U.S. study NANOPULSE-AF, marking a significant advancement in its atrial fibrillation program, with plans to recruit approximately 215 participants to evaluate the safety and effectiveness of its nPulse Cardiac Catheter System.
- High Success Rate: The system achieved a 96% procedural success rate in its European first-in-human feasibility study without the need for anti-arrhythmic drugs, indicating its potential to transform traditional catheter ablation methods for atrial fibrillation treatment.
- Technological Edge: The nPulse system utilizes nanosecond pulsed field ablation technology, achieving a median left atrial dwell time of 21 minutes and a total procedure time of about 65 minutes, significantly enhancing treatment efficiency while minimizing collateral damage to surrounding cardiac tissue.
- Market Potential: The CTO of Pulse Biosciences noted that the first patient enrollment represents an important step based on early feasibility results, and the company will continue to explore applications of this technology in other soft-tissue ablation markets, further solidifying its market position.
See More
Pulse Biosciences Reports Positive Clinical Data for Cardiac Catheter System
- Impressive Clinical Results: Pulse Biosciences presented data at the Heart Rhythm 2026 meeting showing a 100% procedural success rate at 6 months (95/95) and 96% at 12 months (51/53) for its nPulse Cardiac Catheter System, indicating high efficacy and durability in treating atrial fibrillation.
- Enhanced Procedural Efficiency: The system demonstrated a left atrial dwell time of 18.6 minutes, total procedure time of 60.2 minutes, fluoroscopy time of 9.4 minutes, and an average of 12.3 applications per patient, suggesting significant improvements in procedural execution that could enhance patient treatment experiences.
- Maintained Safety Profile: Among 177 patients, only 3 (1.7%) experienced serious adverse events related to the primary safety endpoint, underscoring the safety of the technology in clinical applications and boosting confidence among physicians and patients alike.
- Multi-Center Study Validation: Conducted across 7 investigators in Europe with 177 patients, the consistency and durability of results provide a solid foundation for future clinical applications, potentially driving widespread adoption of this technology in atrial fibrillation treatment.
See More
Pulse Biosciences Reports Positive Clinical Data for Cardiac Catheter System
- Clinical Data Highlights: Pulse Biosciences presented positive clinical data for its nPulse Cardiac Catheter System at the Heart Rhythm meeting, showing a 100% procedural success rate at 6 months among 95 patients, indicating high efficiency and durability of the technology.
- Significant Long-term Outcomes: At the 12-month follow-up, 96% of 53 patients achieved procedural success, with a 90% freedom rate from atrial fibrillation, underscoring the potential and reliability of this technology in treating atrial fibrillation.
- Enhanced Procedural Efficiency: The average procedure time was 60.2 minutes with an 18.6-minute left atrial dwell time, demonstrating consistency and efficiency across multiple investigator sites, which could redefine treatment standards for atrial fibrillation ablation.
- Good Safety Profile: Among 177 patients, only 1.7% experienced serious adverse events related to the primary safety endpoint, indicating the clinical safety of the technology and enhancing its competitive position in the market.
See More
Pulse Biosciences Showcases nPulse Technology at HRS 2026
- Clinical Trial Updates: Pulse Biosciences will present the latest clinical trial results of its nPulse™ cardiac catheter at the 2026 Heart Rhythm Society Annual Meeting, particularly focusing on one-year outcomes from a European feasibility study for atrial fibrillation, which is expected to provide significant long-term data and enhance the company's influence in the cardiac medical market.
- Live Case Transmission: The company will conduct a live case transmission during the PFA Live Case Summit, showcasing the use of nPulse™ technology in treating atrial fibrillation, emphasizing procedural workflow and real-time performance, which will further elevate market awareness and application potential of its technology.
- Multicenter Experience Sharing: At the HRS 2026, Pulse Biosciences will share multicenter experiences using compliant catheters for nanosecond pulsed field ablation to treat atrial fibrillation, which is expected to provide new insights for clinical practice and promote broader application of this technology.
- Innovative Technology Showcase: The company will showcase its innovative nanosecond pulsed field ablation technology at several events, which is anticipated to attract the attention of medical professionals and further solidify its leadership position in the field of bioelectric medicine.
See More
Pulse Biosciences to Host Analyst Event on nPulse Data
- Clinical Data Presentation: Pulse Biosciences will host an analyst event on April 25, 2026, in Chicago, where it will present late-breaking data from its European feasibility study for atrial fibrillation, which is expected to positively influence the company's future clinical development strategy.
- Technology Innovation Overview: The company's proprietary nPulse™ technology employs nanosecond pulsed field ablation (nsPFA™) energy to non-thermally clear cells while sparing adjacent non-cellular tissue, showcasing its potential applications in healthcare.
- Diverse Event Format: The analyst event will be conducted in a hybrid format, offering both in-person and online webcast options, facilitating participation from investors across different regions and enhancing interaction between the company and its investors.
- Replay Availability: Following the event, attendees can access a replay on the company's investor website under the 'Events Calendar and Presentations' section, ensuring that key information is available to those unable to attend live.
See More
Pulse Biosciences Appoints New COO
- Executive Appointment: Pulse Biosciences has appointed Liane Teplitsky as Chief Operating Officer, bringing 20 years of experience in medical technology, including her recent role as CEO of Artedrone, which is expected to enhance operational efficiency and market expansion.
- Role Expansion: David Kenigsberg's role has been expanded to full-time Chief Medical Officer, indicating the company's commitment to strengthening its medical leadership, aimed at enhancing product development and clinical strategy to support future business growth.
- Market Performance: In pre-market trading, PLSE shares were priced at $19, down 0.31%, reflecting a cautious market sentiment regarding the company's new appointments, which may impact investor confidence.
- Industry Background: Teplitsky has held senior marketing and commercial leadership roles at Abbott Laboratories and St. Jude Medical, and her extensive industry experience is expected to bring new perspectives and strategic direction to Pulse Biosciences.
See More
Pulse Biosciences Launches Atrial Fibrillation Study with First Patient Enrollment
- Trial Launch: Pulse Biosciences has enrolled the first patients in its pivotal U.S. study NANOPULSE-AF, marking a significant advancement in its atrial fibrillation program, with plans to recruit approximately 215 participants to evaluate the safety and effectiveness of its nPulse Cardiac Catheter System.
- High Success Rate: The system achieved a 96% procedural success rate in its European first-in-human feasibility study without the need for anti-arrhythmic drugs, indicating its potential to transform traditional catheter ablation methods for atrial fibrillation treatment.
- Technological Edge: The nPulse system utilizes nanosecond pulsed field ablation technology, achieving a median left atrial dwell time of 21 minutes and a total procedure time of about 65 minutes, significantly enhancing treatment efficiency while minimizing collateral damage to surrounding cardiac tissue.
- Market Potential: The CTO of Pulse Biosciences noted that the first patient enrollment represents an important step based on early feasibility results, and the company will continue to explore applications of this technology in other soft-tissue ablation markets, further solidifying its market position.
See More
